Wellington Management Group LLP Has $407 Million Holdings in Vaxcyte, Inc. $PCVX

Wellington Management Group LLP increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 24.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,001,565 shares of the company’s stock after buying an additional 1,386,968 shares during the period. Wellington Management Group LLP’s holdings in Vaxcyte were worth $407,001,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Royal Bank of Canada raised its position in shares of Vaxcyte by 115.2% in the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after acquiring an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Vaxcyte during the 1st quarter valued at about $219,000. Caxton Associates LLP bought a new stake in shares of Vaxcyte during the 1st quarter valued at about $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after purchasing an additional 41,034 shares during the period. Finally, Cetera Investment Advisers grew its stake in Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after purchasing an additional 932 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $59.83 on Friday. The business has a 50-day simple moving average of $57.48 and a 200 day simple moving average of $55.99. Vaxcyte, Inc. has a one year low of $30.32 and a one year high of $65.00. The firm has a market capitalization of $8.90 billion, a price-to-earnings ratio of -7.84 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the business posted ($1.22) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 22,461 shares of Vaxcyte stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $52.50, for a total value of $1,179,202.50. Following the completion of the sale, the chief executive officer owned 474,703 shares of the company’s stock, valued at approximately $24,921,907.50. This trade represents a 4.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the sale, the chief financial officer owned 104,395 shares of the company’s stock, valued at $5,979,745.60. This trade represents a 8.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,646 shares of company stock valued at $6,570,810 in the last 90 days. 3.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PCVX has been the topic of several recent analyst reports. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.